1 / 15

MGNS

MGNS. Heidi Johnson-Gazzard IBD CNS, City Hospital, Birmingham. INFLIXIMAB. INFLIXIMAB WAS LICENSED AS A TREATMENT FOR SEVERE CROHNS DISEASE IN ADULTS IN AUGUST 1999 SINCE THEN, THE NUMBERS OF PTS RECEIVING INFLIXIMAB HAS GROWN SIGNIFICANTLY ITS USE IS NOW COMMONPLACE IN MANAGING SEVERE IBD.

ena
Download Presentation

MGNS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MGNS Heidi Johnson-Gazzard IBD CNS, City Hospital, Birmingham.

  2. INFLIXIMAB • INFLIXIMAB WAS LICENSED AS A TREATMENT FOR SEVERE CROHNS DISEASE IN ADULTS IN AUGUST 1999 • SINCE THEN, THE NUMBERS OF PTS RECEIVING INFLIXIMAB HAS GROWN SIGNIFICANTLY • ITS USE IS NOW COMMONPLACE IN MANAGING SEVERE IBD

  3. INFLIXIMAB • NURSES ARE FREQUENTLY ACCEPTING RESPONSIBILITY FOR PREPARING PTS FOR THERAPY, ENSURING SAFE INFUSIONS & PROVIDING CO-ORDINATED FOLLOW-UP

  4. INFLIXIMAB • COMPLEX AND SEVERE IBD, PLUS THE POTENTIAL SIDE EFFECTS OF INFLIXIMAB OFTEN LEAVE NURSES FEELING APPREHENSIVE REGARDING ITS USE

  5. INFLIXIMAB • INFLIXIMAB IS A MONOCLONAL ANTIBODY (PRODUCED BY A SINGLE CLONE OF CELLS) THAT BINDS WITH HIGH AFFINITY TO TUMOUR NECROSIS FACTOR (TNF) ALPHA, A KEY MEDIATOR OF INFLAMMATION

  6. INFLIXIMAB • BOUND TO INFLIXIMAB, TNF ALPHA IS UNABLE TO OR HAS REDUCED ABILITY TO PARTICIPATE IN THE INFLAMMATORY CASCADE THAT LEADS TO THE MUCOSAL INFLAMMATION AND ULCERATION OF IBD

  7. INFLIXIMAB • REFERRED TO AS TNF INHIBITOR OR “ANTI-TNF” • INFLIXIMAB HAS PROVEN TO BE AN EFFECTIVE TREATMENT IN CROHNS DISEASE AND ULCERATIVE COLITIS, ASWELL AS SEVERAL OTHER AUTO IMMUNE DISEASES (RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIASIS & PSORIATIC ARTHRITIS)

  8. INFLIXIMAB • THE DECISION TO INITIATE INFLIXIMAB TREATMENT SHOULD BE MADE BY THE CONSULTANT, PREFERABLY IN CONJUNCTION WITH A MULTIDISCIPLINARY TEAM EXPERIENCED IN THE MANAGEMENT OF IBD

  9. INFLIXIMAB • IN CROHNS DISEASE, INFLIXIMAB IS INDICATED FOR: SEVERE ACTIVE DISEASE IN ADULTS WHO HAVE NOT RESPONDED DESPITE STEROIDS AND/OR IMMUNOSUPPRESSANTS AND IN THE TREATMENT OF FISTULATING ACTIVE DISEASE WHICH HAS NOT RESPONDED TO CONVENTIONAL TX

  10. INFLIXIMAB • IN CROHNS DISEASE, INFLIXIMAB IS INDICATED FOR: SEVERE ACTIVE DISEASE IN ADULTS WHO HAVE NOT RESPONDED DESPITE STEROIDS AND/OR IMMUNOSUPPRESSANTS AND IN THE TREATMENT OF FISTULATING ACTIVE DISEASE WHICH HAS NOT RESPONDED TO CONVENTIONAL TX

  11. INFLIXIMAB • IN ULCERATIVE COLITIS, INFLIXIMAB IS INDICATED FOR TREATMENT OF MODERATELY–SEVERELY ACTIVE INFLAMMATION IN PTS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY

  12. INFLIXIMAB • THERE MUST BE A DEFINED CLINICAL RESPONSIBILITY AND PROTOCOLS FOR THE PRESCRIBING, ADMINISTRATION AND MONITORING OF BIOLOGICAL THERAPIES, IN AN APPROPRIATE CLINICAL SETTING • OUTCOMES OF BIOLOGICAL THERAPY SHOULD BE REVIEWED REGULARY

  13. INFLIXIMAB • INFLIXIMAB IS ADMINISTERD INTRAVENOUSLY AS A 2 HR INFUSION AT 5MG/KG BODY WEIGHT • IT IS IMPORTANT TO WEIGH THE PT BEFORE EACH INFUSION TO ENSURE THE CORRECT DOSE IS GIVEN

  14. INFLIXIMAB • COST - £??? per 100mg vial • ADMINISTRATION OF INFUSION

  15. INFLIXIMAB • INDUCTION GIVEN AT WEEKS 0,2 & 6. • ONCE PT RESPONSE HAS BEEN ESTABLISHED, MAINTAINENCE THERAPY IS RECOMMENDED • MAINTAINENCE GIVEN EVERY 8 WEEKS

More Related